干扰素α-2b注射液治疗慢性乙型肝炎合并2型糖尿病临床研究  

Interferon α-2b treatment for chronic hepatitis B complicated by type 2 diabetes mellitus

作　　者：亢西 王芳[1] 

机构地区：[1]陕西省汉中市传染病医院肝病中心,723000

出　　处：《传染病信息》2013年第2期115-117,共3页Infectious Disease Information

摘　　要：目的探讨合并2型糖尿病的慢性乙型肝炎(乙肝)患者接受干扰素抗病毒治疗的安全性和有效性。方法 54例慢性乙肝患者中,合并2型糖尿病的18例为治疗组,未合并2型糖尿病的36例为对照组。治疗组在治疗前改用胰岛素控制血糖。2组患者均给予重组人干扰素α-2b注射液5MU皮下注射,隔日1次,疗程1年。疗程结束后分别检测2组的肝功能、空腹血糖及餐后2h血糖,并于治疗后1、12、24周随访检测HBV DNA,比较2组血糖变化及抗病毒应答状况。结果治疗组接受干扰素治疗前后血糖变化差异无统计学意义。治疗组HBV DNA阴转率与对照组相比差异无统计学意义。结论在使用胰岛素进行血糖控制的情况下,合并2型糖尿病并不增加慢性乙肝患者采用干扰素进行抗病毒治疗的风险,也不降低患者对干扰素的应答。Objective To investigate the safety and effectiveness of interferon in the treatment of patients with chronic hepatitis B （CHB） complicated by type 2 diabetes mellitus. Methods A total of 54 CHB patients were included in the study, of whom 18 complicated by type 2 diabetes mellitus were assigned to a treatment group and the other 36 uncomplicated by type 2 diabetes mellitus to a control group. The treatment group was given insulin to control blood glucose levels before treatment. Both the groups re ceived intravenous infusion of 5 million units of recombinant human interferon a-2b every other day for one year. The liver function, fasting blood glucose levels and 2-hour postprandial blood glucose levels of the two groups were detected after treatment, and HBV DNA levels were detected at months 1, 12 and 24 post-therapy as well so as to compare the changes of blood glucose and antiviral response between the two groups. Results Blood glucose levels were not significantly different in the treatment group before and after receiving interferon treatment. HBV DNA negative conversion rates were not significantly different between the treatment group and the control group. Conclusions When blood glucose levels are controlled by insulin, being complicated by type 2 diabetes mellitus will neither increase the risk of interferon treatment in CHB patients nor reduce the antiviral response.

关 键 词：乙型肝炎 慢性 糖尿病 干扰素类 胰岛素 治疗结果 

分 类 号：R512.62[医药卫生—内科学]